Welcome to our dedicated page for UroGen Pharma Ltd. Ordinary Shares news (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on UroGen Pharma Ltd. Ordinary Shares stock.
UroGen Pharma Ltd. (Nasdaq: URGN) is a clinical-stage biopharmaceutical company dedicated to developing innovative non-surgical treatments for urological conditions, particularly uro-oncology. The company is headquartered in Ra’anana, Israel, with its U.S. headquarters in New York.
UroGen’s core technology, RTGel™, is a proprietary sustained-release, hydrogel-based platform designed to improve drug delivery and efficacy. By prolonging the exposure of the urinary tract tissue to medications, RTGel™ aims to make local therapies more effective. This innovative approach addresses significant unmet needs in the field of urology.
The company’s lead product candidates include Mitogel™ (mitomycin urothelial gel) and Vesigel™ (mitomycin intravesical gel). Both products target non-surgical tumor ablation in non-muscle invasive urothelial cancers. Mitogel™ is specifically designed to treat low-grade upper tract urothelial carcinoma, while Vesigel™ aims to treat bladder cancer.
Additionally, UroGen's commercial product, Jelmyto (mitomycin) for pyelocalyceal solution, has shown promise in treating patients. Their investigational candidate, UGN-102 (mitomycin) for intravesical solution, is in development for bladder cancer treatment.
UroGen is also advancing its immuno-uro-oncology pipeline with UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, which is being explored for both monotherapy and combination therapy.
Through strategic partnerships, cutting-edge research, and a commitment to addressing complex medical challenges, UroGen Pharma continues to push the boundaries in the treatment of urothelial diseases.
UroGen Pharma Ltd. (Nasdaq: URGN) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference on
A live audio webcast will be accessible via the company's investor website, with a replay available for approximately 30 days post-event.
UroGen specializes in proprietary technologies, notably RTGel®, a sustained-release hydrogel platform that enhances drug efficacy in treating urinary tract conditions. Its products, including Jelmyto® and investigational UGN-102, aim to non-surgically ablate tumors. UroGen is based in
UroGen Pharma Ltd. reported full-year 2022 net product revenues of $64.4 million, a 34% increase from 2021. The company completed patient enrollment in the ENVISION Phase 3 trial for UGN-102 targeting low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Topline data from pivotal studies is expected mid-2023, with an NDA submission anticipated in 2024. UroGen aims for 2023 JELMYTO revenues between $76 million and $86 million. However, the company reported a net loss of $109.2 million for 2022. As of year-end, cash and equivalents totaled approximately $100 million.
UroGen Pharma Ltd. (NASDAQ: URGN) will report its fourth quarter and full-year 2022 financial results on March 16, 2023, before the stock market opens. A conference call will follow at 10:00 AM ET, accessible via a live webcast on UroGen’s Investor Relations website. The company is focused on innovative treatments for urothelial and specialty cancers, featuring its proprietary RTGel™ hydrogel technology and products like Jelmyto® for non-surgical tumor ablation. UroGen aims to improve therapeutic options for patients through sustained release mechanisms.
UroGen Pharma Ltd. (Nasdaq: URGN) recently granted inducement restricted stock units (RSUs) to 7 new employees from March 1 to March 6, 2023, aimed at bolstering its workforce for the commercial launch of Jelmyto® and ongoing pipeline development. A total of 11,700 shares of common stock will be issued upon RSU vesting over three years, contingent on continued employment. The RSUs align with UroGen’s 2019 Inducement Plan and Nasdaq listing Rule 5635(c)(4). UroGen focuses on innovative treatments for urothelial and specialty cancers, with its first commercial product being Jelmyto®.